Patient Voices Are Redefining Rare Disease Innovation, Say Biotech Leaders
核心洞察
More than 300 million people worldwide live with one of over 7,000 identified rare diseases, yet diagnostic delays average four to five years and can stretch to nine years in the US.
Biotech leaders argue that meaningful innovation requires embedding patient voices into trial design, endpoints, and real-world evidence rather than relying on clinical data alone.
The FALCON study in primary mitochondrial disease (搜索) co-created endpoints with patients, prioritizing fatigue and functional strength as the outcomes that matter most.
More than 300 million people worldwide are living with one of more than 7,000 identified rare diseases, and for many of them, meaningful progress is measured not in clinical milestones but in everyday moments—making breakfast, spending time with family, or simply doing the things they love. That is the central message emerging from biotech leaders who argue that the rare disease field must fundamentally reorient itself around patient voices to deliver innovation that truly changes lives.
"Breakthroughs only matter when they change lives," writes one industry leader with decades at the intersection of science and patient need. "Innovation without empathy is just science. At its best, science changes lives."
The Diagnostic Odyssey
For people living with rare diseases, the path to an accurate diagnosis is often long and fragmented. Across Europe, the average diagnostic delay is nearly five years, and in the United States it can stretch to nine. Patients frequently bounce from specialist to specialist, "often feeling unheard, disbelieved or dismissed," according to the source materials.
Receiving an accurate diagnosis can take four to five years on average and frequently involves multiple specialists and repeated misdiagnoses. During this time, symptoms may progress without a clear explanation or direction, compounding the physical and emotional burden.
The human cost of this delay is illustrated by the case of Adia, a 15-year-old living with the rare genetic disease Activated PI3K Delta Syndrome (搜索) (APDS). She endured recurrent sinus infections throughout childhood, yet genetic testing was not considered until her father passed away from complications related to his own symptoms, including lymphoma. Her eventual diagnosis "changed everything and gave her access to the treatment she needed."
Listening as a Clinical Tool
Patients and caregivers hold deep, practical knowledge of their conditions—"knowledge no algorithm can replicate," the source materials state. Integrating their insights into trial design, endpoints, and real-world evidence is described as "the only way to deliver therapies that truly improve lives."
The FALCON study in primary mitochondrial disease (搜索), now part of Pharming's development pipeline, exemplifies this approach. Instead of imposing traditional endpoints, the study team co-created them with the patient community. Together, they defined what mattered most—fatigue and functional strength—and then developed specific measures to capture those outcomes.
"This is the model we need: solving challenges with patients, not for them," the source states.
The Burden Beyond the Clinic
The impact of rare diseases extends far beyond healthcare settings. In the United States alone, rare diseases are estimated to cost nearly $1 trillion annually. Conditions such as Pompe disease (搜索), limb-girdle muscular dystrophy (搜索), and multiple system atrophy (搜索)—areas of focus for AskBio—place significant demands on patients, families, caregivers, and healthcare systems.
The psychological toll is equally stark. Around 39% of people living with rare diseases experience depression, and more than 44% experience anxiety, considerably higher than in the general population. Pompe disease (搜索), which impacts an estimated 5,000 to 10,000 individuals globally, illustrates one of the biggest challenges in therapeutic development: size. Small patient populations make it inherently more difficult to conduct clinical trials, generate robust datasets, and accelerate research.
Building a Patient-Driven Ecosystem
Rare disease care is "a challenge no single stakeholder can solve alone," the source materials argue. Biotech leaders describe their role as extending beyond developing medicines to redesigning the patient journey so that science and lived experience move in lockstep.
At Pharming, this approach has been operationalized through structured patient feedback loops and rigorous analysis of patient-reported data. These insights shape trial design, guide access strategies, and help shorten the diagnostic odyssey while aligning clinicians, payers, and policymakers.
At AskBio, patient perspectives are integrated throughout development. "They help inform how we design clinical trials, evaluate meaningful outcomes, and make development decisions, challenging us to think differently and innovate with purpose," writes Canwen Jiang, Chief Development Officer and Chief Medical Officer at AskBio.
The source materials outline several foundational steps: engaging patients early in protocol development and advisory boards; building long-term partnerships with advocacy groups; designing for diversity through adaptive trial designs; accelerating diagnosis by pairing AI-enabled tools with clinician training and expanded genetic testing; and planning for access from the start through early payer and health technology assessment dialogues.
Policy as a Multiplier
Policy alignment is described as essential to accelerating patient-first innovation. Protecting orphan drug incentives "makes investment in small populations viable," the source states. In Europe, initiatives like the Draghi report on EU competitiveness and the proposed EU Biotech Act are expected to deliver clearer clinical pathways, smarter use of health data, and earlier diagnosis across borders. France offers a strong example, where expanding its national rare disease plan improved coordination between centers of excellence and reduced diagnostic delays.
In the US, state rare disease advisory councils and expanded newborn screening are closing gaps in testing and care, enabling earlier detection of metabolic disorders and giving families access to treatment before symptoms escalate.
A Collective Path Forward
The source materials frame rare disease innovation as a moral as well as a clinical imperative. "Our responsibility as biotech leaders is clear: Listen deeply. Design with patients, not for them. Act boldly on access," one leader writes.
As gene therapy expands into more diseases and reaches more people, keeping patients' experiences at the center of development is described as essential to delivering innovation that matters most. "When patients are at the heart, science gets sharper, access gets faster, and lives change sooner."